

CLINICAL TRIAL TO TEST EFFECTIVENESS OF HEALTHY HEIGHT® ON CHILDREN UNDERGOING ADHD STIMULANT TREATMENT

HIGHLIGHTS

- **Research agreement with Schneider Children’s Medical Centre to conduct clinical trial to test effectiveness of Healthy Height® on height and weight in children treated with ADHD medication**
- **Clinical Trial to focus on growth parameters and body composition in children treated with stimulant medications for ADHD through a randomised, double-blind, placebo-controlled trial**
- **Approximately five per cent of children are diagnosed with ADHD globally**

5 July 2021 - Nutritional Growth Solutions Ltd. (“the Company” or “NGS”, ASX:NGS), a global nutrition company that creates scientifically formulated and clinically proven supplements to support growth development in children, has signed an agreement for Schneider Children’s Medical Centre to clinically test the effectiveness of Healthy Height® on the height and weight of children treated with stimulant medications for ADHD (Attention Deficit Hyperactivity Syndrome).

Studies report that children treated with stimulants for ADHD may suffer attenuation in height gain both in the short and long term¹, which is why an intervention to increase height gain is needed.

The randomised, double-blind, placebo-controlled clinical trial will be conducted by the Schneider Children’s Medical Centre, the world-renowned specialists in child health and nutrition, where Healthy Height® was created.

About 70-140 children under the age of 10 who are currently being treated for ADHD through prescribed stimulant medication will participate in the trial with half of them supplementing their diet with the Healthy Height® formula and the other half with a placebo product to determine if nutritional intervention with Healthy Height®, increases growth in children treating ADHD with stimulant medication.

¹ Lisska MC, Rivkees SA: Daily methylphenidate use slows the growth of children: A community-based study. J Pediatr Endocrinol Metab 16:711–718, 2003; MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113:762–769, 2004; Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R: Stimulant treatment over 5 years: Effects on growth. J Am Acad Child Adolesc Psychiatry 45:415–421, 2006; Zhang H, Du M, Zhuang S: Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics 41:55–59, 2010; Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, de Castro-Manglano P, Soutullo CA. Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):723-730.



Attention-deficit hyperactivity disorder (ADHD) is a common behavioral disorder for children. Stimulant use is greatest between 6 and 12 years of age, although use among adolescents is also increasing². Systematic reviews indicate the community prevalence globally is between two and seven per cent, with an average of around five percent³.

Liron Fendell, CEO and Managing Director of NGS said,

“ADHD is a prevalent disorder globally with treatment’s adverse side effects including decreased appetite. In the U.S., insurance coverage decisions by commercial insurance and government payers are tied to medical necessity and discreet diagnoses. If the trial provides clear evidence that Healthy Height supports children with an ADHD diagnosis who have been prescribed meds achieve normal growth and counteract the negative effects of the drugs, we believe the payers will be more likely to cover Healthy Height alongside an ADHD diagnosis.”

Healthy Height® is already clinically proven to increase height and weight in short and lean children aged three to nine years old by 13.8% – 34% to their annual growth with no increase in Body Mass Index (BMI) over a one-year period – the only nutritional supplement in the world to able to make this claim.

-ENDS-

This announcement has been authorised for release by the Board of Directors of Nutritional Growth Solutions Ltd.

For more information:

Investors

Mr Brian Leedman
Chairman, Nutritional Growth Solutions
+61 (0) 412 281 780
bleedman@ngsolutions.co

Media

Tristan Everett
Market Eye
+61 403 789 096
tristan.everett@marketeye.com.au

² Zuvekas SH, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012;169:160-166.

³ Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018 Feb;5(2):175-186.



About Nutritional Growth Solutions

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children's Medical Centre, Israel's largest pediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

ngsolutions.co